The remarkable increase of 26% in H1 profit in the shadow of possible recession was the topic of a CNBC interview with Sisram Medical CEO Lior Dayan
Sisram Medical's 2022 Interim Results
Hong Kong-listed Sisram among firms eyeing opportunities in beauty and wellness sector, which could be worth US$7 trillion globally by 2025
CNBC interview with Lior Dayan, Sisram Medical's CEO in light of record 2021 annual results